Gatipotuzumab
CAS No. 1264737-26-9
Gatipotuzumab( —— )
Catalog No. M37170 CAS No. 1264737-26-9
Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 421 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 1093 | Get Quote |
|
| 25MG | 1555 | Get Quote |
|
| 50MG | 2107 | Get Quote |
|
| 100MG | 2808 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGatipotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionGatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.
-
DescriptionGatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).
-
In VitroGatipotuzumab (PankoMab) strongly binds to a short MUC1 peptide of 30 amino acids comprising 1.5 TRs when it is glycosylated with GalNAcα at the T of the PDTRP-sequence, but not if the same peptide is not glycosylated.Gatipotuzumab (PankoMab) (1 h) has a high-affinity towards tumour cells (KD of 0.91, 3.03, 3.84 and 7.14 nM towards NM-D4, ZR75-1, MCF-7 and T-47D, respectively).Gatipotuzumab (PankoMab) (0-5 μg/mL; 4 h) shows specific anti-tumor antibody-dependent cell cytotoxicity activity.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMucin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1264737-26-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6.
molnova catalog
related products
-
Gefapixant citrate
Gefapixant citrate is an orally active P2X3 receptor (P2X3R) antagonist that acts on human homologous recombinant hP2X3 (IC50: ~30 nM) and hP2X2/3 (IC50: 100-200 nM).
-
FKBP12 PROTAC RC32
FKBP12 PROTAC RC32 is a PROTAC-like degrader targeting FKBP12. It can degrade FKBP12 in organs after intraperitoneal administration.
-
VU 0357121
VU0357121, a positive allosteric modulator of mGlu5 (EC50: 33 nM), is inactive or very weakly antagonizing at other mGlu receptor subtypes.
Cart
sales@molnova.com